ReviewBreast (Edinburgh, Scotland)2026

Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.

Mariana Carvalho Gouveia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.